Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma

scientific article

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/1078155211411001
P698PubMed publication ID21807763

P50authorSaif S AhmadQ55426428
P2093author name stringM Lewis
P Corrie
M Iddawela
P2860cites workImproved Survival with Ipilimumab in Patients with Metastatic MelanomaQ27861062
International consensus report on the investigation and management of primary immune thrombocytopeniaQ28262094
A method for estimating the probability of adverse drug reactionsQ29616247
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?Q33205393
Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementQ33384003
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancerQ33389767
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalQ34048270
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic reviewQ36846876
Current systemic therapy for metastatic melanomaQ37483961
Clinical Development of the Anti–CTLA-4 Antibody TremelimumabQ37809151
Current management of metastatic melanomaQ46217401
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).Q51800094
P433issue2
P921main subjectipilimumabQ2459042
patientQ181600
thrombocytopeniaQ585285
metastatic melanomaQ18975855
P304page(s)287-292
P577publication date2011-08-01
P1433published inJournal of Oncology Pharmacy PracticeQ6295681
P1476titleIpilimumab-induced thrombocytopenia in a patient with metastatic melanoma
P478volume18

Reverse relations

cites work (P2860)
Q26858779Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Q52641422Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.
Q33434066Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report
Q89526156Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events
Q37629874Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Q90639031Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management
Q64085283Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
Q26785746Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Q36841621Immunomodulatory therapy for melanoma: ipilimumab and beyond
Q36292634Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.
Q33777476Ipilimumab and its toxicities: a multidisciplinary approach
Q38171355Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells
Q31034415Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Q87997894Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
Q47164715Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
Q89947448Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review
Q27008140Toxicities of Immunotherapy for the Practitioner

Search more.